132330-98-4

Usage

Uses

Used in Medicinal Chemistry Research:
3-(Benzyloxy)-2-bromopyridine is used as a chemical intermediate for the synthesis of more complex compounds in medicinal chemistry research. Its unique structure with a bromine atom and a benzyloxy group allows for further functionalization and modification, enabling the development of novel therapeutic agents.
Used in Organic Synthesis:
In the field of organic synthesis, 3-(Benzyloxy)-2-bromopyridine serves as a versatile building block for the creation of various organic compounds. Its reactivity and functional groups make it suitable for a wide range of chemical reactions, facilitating the synthesis of target molecules with desired properties.
Used in Pharmaceutical Industry:
3-(Benzyloxy)-2-bromopyridine is utilized as a key intermediate in the development of pharmaceutical compounds. Its unique structure and reactivity contribute to the design and synthesis of new drugs with potential therapeutic applications, such as antibiotics, anti-inflammatory agents, and other medicinal agents.

Upstream product

• 6602-32-0 2-bromo-pyridin-3-ol 
• 620-05-3 iodomethylbenzene 
• 100-39-0 benzyl bromide 

Downstream Products

• 184575-16-4 1-(3-Benzyloxy-pyridin-2-yl)-piperazine 
• 263390-63-2 3-benzyloxy-2-(3-ethoxycarbonylphenoxy)pyridine 
• 1173168-85-8 3,3'-bis-(3-benzyloxy-2-pyridyl)-2,2'-dimethoxymethoxy-1,1'-binaphthyl 
• 1580464-56-7 3-(benzyloxy)-2-(trifluoromethyl)pyridine 
• 76509-17-6 3-benzyloxypyridine 

Relevant academic research and scientific papers

Dearomatization through Photoredox Hydroarylation: Discovery of a Radical-Polar Crossover Strategy

Indole dearomatization has been achieved via radical hydroarylation. Under mild photoredox conditions, a range of indole derivatives undergo hydroarylation to form 2-arylindoline products. Mechanistically, radical termination occurs primarily via stepwise

Hydroarylation of Arenes via Reductive Radical-Polar Crossover

A photocatalytic system for the dearomative hydroarylation of benzene derivatives has been developed. Using a combination of an organic photoredox catalyst and an amine reductant, this process operates through a reductive radical-polar crossover mechanism where aryl halide reduction triggers a regioselective radical cyclization event, followed by anion formation and quenching to produce a range of complex spirocyclic cyclohexadienes. This light-driven protocol functions at room temperature in a green solvent system (aq. MeCN) without the need for precious metal-based catalysts or reagents or the generation of stoichiometric metal byproducts.

NOVEL PIPERIDINE DERIVATIVE

The invention provides a compound of the following formula (1): wherein m, n, and p are independently an integer of 0 - 4, provided 3 ≤ m + n ≤ 8; X is nitrogen atom or a group of the formula: C-R15; Y is a substituted or unsubstituted aromatic group, etc.; R15, R1, R2, R3, R4 , R5, R6 and R7 are hydrogen atom, a substituted or unsubstituted alkyl group, etc.; and Z is hydrogen atom, cyano group, etc., or a prodrug thereof, or a pharmaceutically acceptable salt thereof, which exhibits an action for enhancing LDL receptor expression, and is useful as a medicament for treating hyperlipidemia, atherosclerosis, etc.

NOVEL PIPERIDINE DERIVATIVE

A compound of the formula (1): wherein m and n are independently an integer of 0 to 4, and m+n=4; L is cycloalkyl, substituted cycloalkyl, aromatic group, or substituted aromatic group; Y is aryl or substituted aryl; R is hydrogen, alkyl, etc.; R31/

Pyrrolo[2,1,5-cd]indolizine derivatives useful in the prevention or treatment of estrogen related diseases or syndromes

The present invention relates to therapeutically active compounds of formula I a method of preparing the same and to pharmaceutical compositions comprising the compounds. The novel compounds are useful in the prevention or treatment of estrogen related diseases or syndromes.

Synthesis and bioactivity of novel bis(heteroaryl)piperazine (BHAP) reverse transcriptase inhibitors: Structure-activity relationships and increased metabolic stability of novel substituted pyridine analogs

The major route of metabolism of the bis(heteroaryl)piperazine (BHAP) class of reverse transcriptase inhibitors (RTIs), atevirdine and delavirdine, is via oxidative N-dealkylation of the 3-ethyl- or 3-isopropylamino substituent on the pyridine ring. This